Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS : revenue, balance sheet and financial ratios

SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS is a French company founded 21 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MARSEILLE (13006), this company of category PME shows in 2023 a net income positive of 106 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS (SIREN 478251903)
Indicator 2023 2022 2021 2020 2017
Revenue N/C N/C N/C N/C N/C
Net income 106 440 € 111 704 € 130 017 € 45 793 € 100 724 €
EBITDA N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C

Revenue and income statement

In 2023, SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS generates positive net income of 106 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2023: 101 k€ -> 106 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

106 440 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 29%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 67%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

28.818%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

67.093%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

29.5%

Solvency indicators evolution
SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS

Sector positioning

Debt ratio
28.82 2023
2021
2022
2023
Q1: 20.09
Med: 66.92
Q3: 169.24
Good -8 pts over 3 years

In 2023, the debt ratio of SELARL PHARMACIE D. BOUDO... (28.82) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
67.09% 2023
2021
2022
2023
Q1: 28.72%
Med: 48.51%
Q3: 68.17%
Good +10 pts over 3 years

In 2023, the financial autonomy of SELARL PHARMACIE D. BOUDO... (67.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 116.43. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

116.432

Liquidity indicators evolution
SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS

Sector positioning

Liquidity ratio
116.43 2023
2021
2022
2023
Q1: 135.25
Med: 189.78
Q3: 270.35
Watch

In 2023, the liquidity ratio of SELARL PHARMACIE D. BOUDO... (116.43) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Positioning of SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2023, the value of SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS is estimated at 1 255 936 € (range 763 794€ - 1 765 564€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
220 transactions
763k€ 1255k€ 1765k€
1 255 936 € Range: 763 794€ - 1 765 564€
NAF 5 année 2023

Valuation method used

Net Income Multiple
106 440 € × 11.8x = 1 255 936 €
Range: 763 795€ - 1 765 565€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS

What is the revenue of SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS ?

The revenue of SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS profitable?

Yes, SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS generated a net profit of 106 k€ in 2023.

Where is the headquarters of SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS ?

The headquarters of SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS is located in MARSEILLE (13006), in the department Bouches-du-Rhone.

Where to find the tax return of SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS ?

The tax return of SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS operate?

SELARL PHARMACIE D. BOUDOURESQUE ET J. KOSKAS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.